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Introduction
The -thalassemias comprise a group of inherited disorders of hemoglobin synthesis primarily existing in the low-or middle-income countries of the tropical belt stretching from sub-Saharan Africa, through the Mediterranean region and the Middle East, to South and Southeast Asia.
Continued migration has also greatly expanded the reach of these diseases into large, multiethnic cities in Europe and North America; thus making such disorders a global public health concern. 1 Distinction of the various forms of -thalassemia relies on clinical grounds. Patients withthalassemia major present to medical attention in early childhood with severe anemia requiring life-long transfusion and iron chelation therapy for survival. 2 Conversely, patients withthalassemia intermedia present later in childhood with milder anemia and remain largely transfusion-independent. 3 Such variation in phenotype has been attributed to several environmental and genetic factors that alter the / -chain imbalance and subsequent ineffective erythropoiesis and peripheral hemolysis, the hallmarks of disease process in -thalassemia. 4 Among the sequelae associated with a diagnosis of -thalassemia, pulmonary arterial hypertension (PAH) has received great attention in recent years. 5 Prevalence rates exceeded 50% in some studies. Although the exact mechanisms implicated in the pathogenesis of PAH inthalassemia remain unclear, its association with several risk factors and with subsequent rightsided heart failure have been illustrated. [5] [6] The main concern is that most available studies that evaluated PAH in patients with -thalassemia established the diagnosis solely based on echocardiographic criteria, without systematic confirmation on right heart catheterization, a procedure that is recommended in international guidelines as the standard of care. [7] [8] [9] More importantly, recent evidence from patients with sickle cell disease (SCD) echoed earlier studies in other conditions which established that the use of echocardiography alone results in a halassemia intermedia present later in childhood with milder anemia and remain in n lar ar arge ge ely ly ly r ransfusion-independent. 3 Such variation in phenotype has been attributed to several en nvi vi viro ro ron nm nmen en enta ta tal an an nd d d g genetic factors that alter the / / / --chain imbalan n nce c a and nd nd s subsequent ineffective er ryt t th hropoiesis s a and nd nd p per er rip p phe he hera ra ral l l h he hem mo moly ly l s si is s, , the e e h h hallm m ma a arks s s o o of f d d dis se eas ase pr proc oces ess s in in n -t -tha ha ala la ass ss s em em emia ia ia. . 4 4 4 A Amo mo mon ng ng t the he he s seq eq que ue ela lae a as a so so oci ci ciat at a ed ed d w w wit it ith h h a a di di d a ag agn no nos si sis of of of -t -t -tha ha hala lass ss ssem em emia a a, , pu pu ulm lm mon on nar ar ary y a a arte te eri ria al al hypertension n ( ( (PA PA PAH) H) H) h h has as as rec ec ecei ei eive ve ed d d gr gr rea e e t t t at at atte te tent nt ntio io ion n n in in in r r rec ec e en en ent t ye ye year ar rs. s. s. 5 10 Hence, the true prevalence of PAH in patients with -thalassemia remains unidentified. Such information not only has implications on health care utilization measures, but will also aid in proper interpretation of available studies highlighting risk factors and outcomes associated with PAH in this patient population. In this line, we aimed to evaluate the prevalence of PAH in a large group of patients with -thalassemia using standard diagnostic criteria involving confirmatory right heart catheterization. The role of several risk factors was also evaluated.
Methods

Participants
This was a multicenter cross-sectional study of -thalassemia patients followed at eight thalassemia comprehensive care centers taking part of the Italian Webthal® project. Webthal® is a computerized clinical record network for all thalassemia patients attending the participating centers, and is commonly utilized for collaborative research studies. We included all adult ( 18 years) patients with a diagnosis of -thalassemia major or intermedia defined as per standard criteria 11 (n=1330); and excluded patients with chronic restrictive lung disease or a left ventricular ejection fraction of 50% on last echocardiography in whom pulmonary hypertension, if confirmed, would not be classified as PAH but would be attributed to left-heart or lung disease (n=21). A total of 1309 patients were eligible for the study. The study was conducted over a 12 month period (20 January 2012 -20 January 2013). The institutional review boards at all participating center approved the study protocol and all participants signed a written informed consent prior to inclusion (ClinicalTrials.gov Identifier: NCT01496963).
Study design and measurements
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For all eligible patients, data were retrieved for demographics (age and sex), splenectomy status, as well as mean hemoglobin (pre-transfusional in transfused patients) and serum ferritin levels over the previous 10 years. Measurements were then conducted over two phases. During the first six months, all eligible patients underwent a screening transthoracic echocardiography as part of their standard thalassemia follow up and management. 11 We used continuous-wave Doppler sampling of the peak tricuspid-valve regurgitant jet velocity (TRV) to calculate the pulmonary arterial systolic pressure (sPAP), as described previously. [12] [13] [14] The echocardiographic acquisitions in transfusion-dependent patients were performed in the early post-transfusional period. Accordingly, patients were divided into three groups according to the European Society ESC guidelines. 7 PH was established with a mean pulmonary arterial pressure (mPAP) of 25 mm Hg and PAH was confirmed with a pulmonary capillary wedge pressure (PCWP) 15 mm Hg (pre-capillary PH). 7 In patients with confirmed PAH, we also retrieved values for cardiac index, pulmonary vascular resistance, vasoreactivity (a positive acute response was defined as a reduction of mPAP of 10 mm Hg to reach an absolute value of 40 mm Hg with an increased or unchanged cardiac output 8 ; and assessed patients functionality using the New York Heart Association Functional Classification (NYHA) 15 and a 6-minute walk test.
Statistical analysis
Descriptive statistics are presented as means ± standard deviation (SD), medians and interquartile range (IQR), or percentages. Bivariate comparisons between groups were carried out using the independent samples t-test or Mann Whitney U test for continuous variables and the Chi-squared test for categorical variables. Correlations between sPAP values were made using the Pearson's correlation coefficient (r). A multivariate logistic regression model was constructed to establish the independent role of risk factors on the outcome of confirmed PAH, by calculating the odds ratios (OR) and 95% confidence intervals (95%CI). All risk factors with a significant association with the outcome on univariate analysis were entered into the model.
Regression models were adjusted for the confounding effect of the centre at which the patient is treated by creating and adjusting for a variable with categories pertaining to each participating centre. This information was added to the statistical analysis section.All p-values were two-sided with the level of significance set at 0.05.
Results
Patients' characteristics
A total of 1309 patients were recruited in this study. The mean age was 36. The mean hemoglobin level was 9.3 ± 0.7 g/dl (range: 6.0-13.4) while the median serum ferritin level was 1072.8 (IQR: 574-1868, min: 5, max: 14142). Patients with -thalassemia intermedia were older, more commonly splenectomized, and had lower hemoglobin and serum ferritin levels than patients with -thalassemia major ( Table 1) .
Prevalence of pulmonary arterial hypertension
The study flow chart is illustrated in Table 2 .
There was a modestly good correlation between sPAP estimated on transthoracic halassemia ma ma majo jo jor: r: r: 1 1 1.6 .6 6%, %, % 9 9 95% 5% 5%CI CI CI: : : 1. 1. .0-0 2. 2. 2 6; 6; 6; -t -t tha ha hala la ass ss s em em e ia ia a i int nt n er er erme me medi dia: a: a 9 9 9.3 .3 3%, %, %, 9 95% 5% 5%CI CI CI: : : 6. 6. 6 7-12.6) if f echocardiography and measured on right heart catheterization (Figure 2) . The positive predictive value for the TRV 3.2 m/s threshold for the diagnosis of PH was 93.9%.
Risk factors for pulmonary arterial hypertension
Compared to patients in Group A (PH unlikely on echocardiography), patients with right heart catheterization confirmed PAH were older, more likely to be -thalassemia intermedia than major, and more commonly splenectommized ( This indicated that the marked increase in confirmed PAH risk in -thalassemia intermedia compared with -thalassemia major was primarily confounded by older age and only minimally mediated through an increased propensity for splenectomy (see Table 1 ). Upon adjustment for both factors (age and splenectomy status), a nearly two-fold non-significant yet independent increase in confirmed PAH risk is noted in -thalassemia intermedia compared withthalassemia major (OR: 1.80, 95%CI: 0.71-4.57).
On multivariate logistic regression analysis including significant variabl les es s a a at t t th th he e univariate level (age, -thalassemia phenotype, and splenectomy status) the only independent i ign gn nif if ific ic ican an nt t t ri ri ris s sk f f fac ac acto tors for having confirmed PA A AH H H w w were: age (OR: R: : 1.102 02 02 p per 1-year increase,
Discussion
This is the first large study to evaluate the prevalence of PAH in patients with -thalassemia using standard guidelines and confirmatory right heart catheterization. Previous studies relying solely on echocardiographic parameters, reported prevalence rates ranging between 10% and 78.8% (averaging at ~30%). [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] The diagnosis was usually established based on a TRV exceeding 2.5-2.8 m/s corresponding to an sPAP exceeding 30-35 mm Hg, with some studies including symptomatology within the definition. 16, 18, 20, 22, 24, [26] [27] [28] [29] [31] [32] [33] In our study, the prevalence of PAH was considerably lower when more strict echocardiographic criteria and confirmatory right heart catheterization were used. Owing to the systematic approach undertaken in our study, we believe that estimates presented in this report are more likely representative of the true PAH prevalence in patients with -thalassemia. Our study echoed previous reports demonstrating that the prevalence of PAH is higher in -thalassemia intermedia thanthalassemia major [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] ; but did not observe the previously reported female predominance. 34 35 The correlation between sPAP as estimated on echocardiography and as measured on right heart catheterization was only moderately good in our study. There may be several reasons for the discrepancy between these two methods, including the imprecision of the echocardiographic measurement, inherent physiological variations in pulmonary hemodynamics, as well as the interval between echocardiography and catheterization. 10 When a threshold TRV of 3.2 m/s is used to define PH, the positive predictive value of echocardiography was as high as 93.3%. However, we could not determine the false negative rate of this threshold nor the predictive power of lower thresholds (2.5 or 2.8 m/s) utilized in other studies; since such patients did not undergo right heart catheterization in our study which followed the ESC guidelines for the diagnosis of PH, used higher TRV thresholds in light of the chronic severe anemia in n our study, we believe that estimates presented in this report are more likely rep ep pre e ese s s nt nt ntat at ativ iv ive e e o of he true PAH prevalence in patients with -thalassemia. Our study echoed previous reports de emo mo mons ns nst tr trat at atin in ing g g th h hat at at t the prevalence of PAH is high gh gher r r in -thalassem m mia i int nt nte er ermedia thanh h hal l las a semia ma majo jo jor 16-16-33 33 33 ; ; bu bu but t t di di did d d no not t t o ob obs se er rv ve t th he e e prev ev evi iou us usl ly ly r rep ep por ort te ed d d fe fem m mal le le p p pre re edo domi m min na nan nce. e. e. 34 thalassemia patients, and considered it inappropriate to perform an invasive procedure for asymptomatic patients with lower TRV thresholds, especially considering the findings of a high false positive rate in the recent study from patients with SCD. 10 Thus, although we can confirm that relying on such a threshold to diagnose PH is justified, we cannot exclude that several patients with PH would not be detected with such a threshold.
Similar to patients with SCD and other chronic hemolytic anemias, pulmonary hypertension in -thalassemia patients would be classified as PAH (Class 1) in international guidelines; which is characterized by the presence of pre-capillary pulmonary hypertension in the absence of left-sided heart disease (Class 2), lung disease (Class 3), or chronic thromboembolism (Class 4). [7] [8] 36 Although pulmonary hypertension can occur in -thalassemia patients in the setting of siderotic left-ventricular dysfunction, pulmonary hemosiderosis and subsequent fibrosis 37 , and chronic thromboembolic disease 22, [38] [39] ; these remain less commonly reported pulmonary hypertension settings (classes) and such patients would have been excluded from our study which exclusively aimed to evaluate PAH. Nonetheless, and similar to patients with Class 4 pulmonary hypertension attributed to chronic thromboembolic disease, hypercoagulability can play a major role in the etiology of PAH; where thrombi may be present in both the small distal pulmonary arteries and the proximal elastic pulmonary arteries. 7 The association of splenectomy and older age with increased PAH risk in our study echoes previous reports 18-19, 22, 24-25, 33, 35, 39-41 and further supports the latter hypothesis. Abnormalities of platelets and hemolyzed red blood cells are believed to be the key factors causing hypercoagulability and subsequent thrombotic events in -thalassemia; especially older, splenectomized, -thalassemia intermedia patients. 42 The association of thrombocytosis, increased platelet activation, increased levels of nucleated red blood cells, and other markers of hypercoagulability with PAH in patients with -thalassemia Class 4). [7] [8] 36 Although pulmonary hypertension can occur in -thalassemia pat tie ie ient nt nts in in in t t the he he etting of siderotic left-ventricular dysfunction, pulmonary hemosiderosis and subsequent fibr br ros os osis is is 37 37 37 , a a and n n c chr hr hron onic thromboembolic disease e 22 (mostly intermedia) has been reported, even in patients with no evidence or history of pulmonary embolic disease. 19, 24-25, 34, 39, 43 Other factors are also suggested to cause PAH in -thalassemia. Associations between lower hemoglobin levels and increased markers of hemolysis with this morbidity have been reported. 22, 25, [34] [35] The process of hemolysis disables the arginine-nitric oxide pathway through the simultaneous release of erythrocyte arginase and cell-free hemoglobin. Both nitric oxide and its obligate substrate arginine are rapidly consumed. The biological consequences of hemolysis on nitric oxide bioavailability ultimately translate into pulmonary vasoconstriction and the clinical manifestations of PAH. 6, 44 The causal association of this pathway with PAH in patients with SCD, however, has been challenged. 45 PAH is also associated with increased expression of endothelin receptors in pulmonary microvascular endothelial cells and monocytes, due to intrinsic high levels of placenta growth factor in patients with SCD and -thalassemia. 46 An association between iron overload (or absence of chelation therapy) and PAH has also been observed in patients with -thalassemia. 17, 22, 31, 39, [47] [48] [49] Iron is implicated in the pathogenesis of several vascular disorders including atherosclerosis, arterial thrombosis, microangiopathic hemolytic anemia, vasculitis, and reperfusion injury in non-thalassemic populations. 50 The presence of non-transferrin-bound iron in the sera of -thalassemia patients can cause oxidative vessel injury and endothelial activation. 51 Moreover, iron overload could lead to hepatic disease and subsequent alterations in coagulation factor levels, thus worsening the hypercoagulable state implicated in these patients. 42, 52 However, we did not observe a role for iron overload in this study. Patients with -thalassemia receiving regular transfusions may also be at risk of PAH due to transfusion-related HIV infection. 53 The etiology of PAH in -thalassemia is thus most likely multifactorial, involving a complex interaction of platelets, the coagulation system, erythrocytes, with SCD, however, has been challenged. 45 PAH is also associated with increased ed d e e exp xp pre r ress ss ssio io ion n o of endothelin receptors in pulmonary microvascular endothelial cells and monocytes, due to n ntr tr rin in insi si sic c hi hi high gh gh lev v vel el els s of placenta growth factor in n n p p pa at tients with SCD CD D and nd d -thalassemia. 46 -Thalassemia patients with confirmed PAH in this report had a more marked increase in mPAP and pulmonary vascular resistance than what has been reported in patients with SCD. 10 They also has a similarly high rate of functional limitation (NYHA) and considerable decrease in the 6-minute walk distance. 10 This parallels studies confirming that PAH in -thalassemia is a serious morbidity associated with subsequent right ventricular dysfunction 28, 30, 38, 49, [55] [56] [57] , and warranting prompt diagnosis and treatment. The higher prevalence of PAH in -thalassemia intermedia compared with -thalassemia major patients, suggests a protective role for transfusion therapy in this setting. Even in patients with -thalassemia intermedia, the administration of transfusion therapy is associated with lower PAH rates. 39 Transfusions not only improve anemia and hemolysis, but may also have a role in ameliorating the hypercoagulable state in this disease. 26, 42, 58 Similar effects may be attained with hydroxycarbamide (fetal hemoglobin inducer) 59 therapy and a role of this agent in PAH prevention has been observed. 23, 39, [60] [61] Sildenafil citrate, a potent inhibitor of cyclic guanosine monophosphate-specific phosphodiesterase-5 and a selective smooth muscle relaxant, showed promising results for the management of PAH in small studies in -thalassemia patients. [62] [63] [64] More recently, a large multicentre trial on patients with thalassemia showed that sildenafil therapy may improve cardiopulmonary hemodynamics in patients at risk for PH (TRV >2.5 m/s). 65 Bosentan (endothelin receptor antagonist) and epoprostenol (prostacyclin) were also reported to be effective in some patients. 3, [66] [67] Results from ongoing and future clinical trials will help structure management guidelines for PAH in -thalassemia, which have not yet been established. 6 In conclusion, our study provided the first right heart cauterization confirmed prevalence estimate for PAH in -thalassemia patients. We confirmed a higher PAH prevalence in patients ransfusion therapy is associated with lower PAH rates. 39 Transfusions not only i imp mp mpro ove ve ve a a ane ne nem mia and hemolysis, but may also have a role in ameliorating the hypercoagulable state in this di ise se eas as ase e. e. 26 .9 ( (17 5 . ) ) t t e he hear ar a t t ca ca cath th thet et eter er e iz izat at atio i n n n P, me mean an ( (SD SD) ) 44 2) ) ac index in l m m /min in in/m /m /m 2 2 2 , me mean an a ( (SD SD S ) 3 3.6 6 6 (1 (1 ( 1 .1 1) ) 3 3. 3 2 2 1 (1.0 0 0) ) 3.8 (1.1) Table 3 . Risk factor analysis. Fi Fi Figu g re re e 3 3. . . Pro rob ba bab bility of having pulmonary arte teri r r a a al hypertension n (P ( ( AH AH H) ) ) c confirmed on right he h art cath het ete er riz z zat tio io on as as a a f f fu un unct ctio io ion n n o of f a a age i in n a all p p pat t tien n nts ts ts a as s we well ll a a as acco cord rdin ing g g to to o s spl pl len en e ec ec e t to om my my st st stat at a us us. . Pr Pr Prob oba ab bi il lit ity y y fo form rmul la a a wa wa was s s de de deri riv ve ved d d fr fr from om om th the e e l lo ogi gi ist tic ic ic r r reg eg egre re ress ss sio o on n n eq eq qua a ati tion on n u u usi si s ng ng ng t t th he f foll llowin ing g eq eq equa ua ati ti ion on n: : Pr P P ob ob obab ab abil ilit it ity y y of of of PAH AH AH = e e exp xp xp( (Z-Z Z va va valu lue) e) e)/[ /[ /[1+ 1+ 1 ex ex xp( p( p(Z-Z-va va valu lu lue) e) e)] ] ] wh wh w er er e e e e Z-Z Z va va valu lue i is
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